ArticleCureus2025
Successful Treatment of Disseminated Carcinomatosis of the Bone Marrow Secondary to Colorectal Cancer With Modified FOLFOX6 Plus Panitumumab: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disseminated Carcinomatosis of the Bone Marrow in Colorectal Cancer: A Case Series of Two Patients with Rapidly Fatal Outcomes.Surgical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disseminated carcinomatosis of the bone marrow (DCBM) is a rare, aggressive manifestation of colorectal cancer (CRC). It is often accompanied by pancytopenia and disseminated intravascular coagulation (DIC) and has a poor prognosis. Herein, we present the case of a 61-year-old male patient with sigmoid colon cancer and DCBM who presented with fever, fatigue, and DIC. Bone marrow biopsy confirmed poorly differentiated adenocarcinoma, consistent with the primary tumor. Genetic testing revealed the RAS and BRAF wild-type status. The patient was administered modified FOLFOX6 plus panitumumab as first-line chemotherapy. The patient's clinical symptoms improved rapidly, and transfusion dependency resolved after two cycles of chemotherapy. Subsequent comprehensive genomic profiling identified a subclonal
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.